Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Actinogen Medical Limited (ACW.AX)
AUD0.04
+0.00 (+0.00%)
AU ASX Healthcare Biotechnology
Address
109 Pitt Street 2000
Sydney, NSW, AU
Sydney, NSW, AU
CEO
Steven G. Gourlay
Website
actinogen.com.au
IPO
2007-10-16
ISIN AU000000ACW3
Also trades on
Australian Securities Exchange · ACW.AX (AUD)
Other OTC · ATGGF (USD)
Description
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.04
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.85
Float Shares
2.69B
Free Float %
75.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.56% | -2.56% | -11.63% | -7.32% | -36.67% | -37.70% | +80.95% | -12.80% | -65.12% | -55.02% | -94.22% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.04
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
15.12
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-44.7% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+18.3% Q4'25: +26.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-82.4%
-
EBIT margin Biotechnology: +0.0%-279.7%
-
ROIC Biotechnology: -16.1%-301.3% Q4'25: -2,069.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+37.0% Q4'25: +36.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.22× Q4'25: -0.01× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.86M
est: 4.00M (+21.6%)
|
3.52M
est: 3.00M (+17.2%)
|
1.98M
est: 3.00M (-33.9%)
|
3.64M
est: 2.50M (+45.6%)
|
4.89M
est: 4.64M (+5.3%)
|
9.93M
est: 7.90M (+25.7%)
|
5.49M
est: 7.12M (-22.9%)
|
11.01M
11.01M – 11.01M
+54.6% YoY
|
10.10M
10.10M – 10.10M
-8.2% YoY
|
16.14M
16.14M – 16.14M
+59.7% YoY
|
23.12M
23.12M – 23.12M
+43.3% YoY
|
76.90M
76.90M – 76.90M
+232.6% YoY
|
| EBITDA |
-9.25M
est: -4.00M (-131.3%)
|
-8.20M
est: -7.42M (-10.5%)
|
-5.35M
est: -3.00M (-78.2%)
|
-12.72M
est: -4.69M (-171.2%)
|
-15.22M
est: -4.11M (-270.3%)
|
-12.84M
est: -7.90M (-62.5%)
|
-15.01M
est: -7.12M (-110.8%)
|
-11.01M
-11.01M – -11.01M
-54.6% YoY
|
-10.10M
-10.10M – -10.10M
+8.2% YoY
|
-16.14M
-16.14M – -16.14M
-59.7% YoY
|
-23.12M
-23.12M – -23.12M
-43.3% YoY
|
-76.90M
-76.90M – -76.90M
-232.6% YoY
|
| EBIT |
-9.61M
est: -4.00M (-140.2%)
|
-8.62M
est: -11.06M (+22.1%)
|
-5.73M
est: -3.00M (-91.1%)
|
-13.12M
est: -7.72M (-70.0%)
|
-15.62M
est: -6.76M (-131.0%)
|
-13.26M
est: -7.90M (-67.8%)
|
-15.35M
est: -7.12M (-115.6%)
|
-11.01M
-11.01M – -11.01M
-54.6% YoY
|
-10.10M
-10.10M – -10.10M
+8.2% YoY
|
-16.14M
-16.14M – -16.14M
-59.7% YoY
|
-23.12M
-23.12M – -23.12M
-43.3% YoY
|
-76.90M
-76.90M – -76.90M
-232.6% YoY
|
| Net Income |
-9.89M
est: -27.66M (+64.3%)
|
-5.33M
est: -7.42M (+28.1%)
|
-3.92M
est: -30.43M (+87.1%)
|
-9.50M
est: -4.66M (-103.6%)
|
-10.75M
est: -4.09M (-163.0%)
|
-13.04M
est: -17.88M (+27.0%)
|
-14.73M
est: -11.92M (-23.6%)
|
-12.81M
-12.81M – -12.81M
-7.5% YoY
|
-29.80M
-29.80M – -29.80M
-132.6% YoY
|
-29.80M
-29.80M – -29.80M
+0.0% YoY
|
-47.97M
-47.97M – -47.97M
-61.0% YoY
|
-1.49M
-1.49M – -1.49M
+96.9% YoY
|
| SGA |
3.22M
est: 5.10M (-36.8%)
|
2.96M
est: 590.1K (+401.9%)
|
3.11M
est: 3.82M (-18.6%)
|
4.56M
est: 1.94M (+135.3%)
|
6.57M
est: 1.70M (+286.9%)
|
7.24M
est: 10.07M (-28.1%)
|
8.13M
est: 9.08M (-10.5%)
|
14.03M
14.03M – 14.03M
+54.6% YoY
|
12.88M
12.88M – 12.88M
-8.2% YoY
|
20.57M
20.57M – 20.57M
+59.7% YoY
|
29.47M
29.47M – 29.47M
+43.3% YoY
|
98.01M
98.01M – 98.01M
+232.6% YoY
|
| EPS |
-0.01
est: -0.01 (+3.1%)
|
0.00
est: -0.01 (+30.8%)
|
0.00
est: -0.01 (+73.6%)
|
-0.01
est: -0.01 (+6.8%)
|
-0.01
est: 0.00 (-20.3%)
|
-0.01
est: -0.01 (+0.0%)
|
0.00
est: 0.00 (-22.5%)
|
0.00
0.00 – 0.00
-7.5% YoY
|
-0.01
-0.01 – -0.01
-132.6% YoY
|
-0.01
-0.01 – -0.01
+0.0% YoY
|
-0.02
-0.02 – -0.02
-61.0% YoY
|
0.00
0.00 – 0.00
+96.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-24.98M
OE per share TTM
0.05
Owner's Yield
-20.63%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | — | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-25.6K
Shares Outstanding
3.59B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dana C. Hilt | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 651.0K | — |
| Steven G. Gourlay FRACP MBBS | MD, Chief Executive Officer & Director | 562.3K | — |
| Andrew Udell | Chief Commercial Officer | 483.0K | male |
| William Edward Souter IPAA | Chief Financial Officer | 459.8K | male |
| Paul Edward Rolan | Head of Clinical Pharmacology & Lead Physician and Depression | 94.6K | — |
| Paul Rolan | Head of Clinical Pharmacology & Lead Physician and Depression | 94.6K | — |
| Peter Gordon Webse FCIS FCPA FGIA | Company Secretary | — | male |
| Michael Roberts | Head of Investor Relations & Corporate Communications | — | male |
| Fujun Li | Head of Manufacturing | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACW.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
